Hutchison China MediTech Limited : Pharmaceuticals and Healthcare - Company Profile, SWOT & Financial Analysis
SynopsisICD Research's "Hutchison China MediTech Limited : Pharmaceuticals and Healthcare - Company Profile, SWOT & Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company history, financial analysis, mergers & acquisitions, recent developments, key employees, company locations and subsidiaries as well as competitive benchmarking data.
Summary
This report is a crucial resource for industry executives and anyone looking to access key information about "Hutchison China MediTech Limited"
The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
• Examines and identifies key information and issues about "Hutchison China MediTech Limited" for business intelligence requirements.
• Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
• Provides data on company financial performance and competitive benchmarking.
• The profile also contains information on business operations, company history, major products and services, key employees, and locations and subsidiaries.
Reasons To Buy
• Quickly enhance your understanding of "Hutchison China MediTech Limited"
• Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
• Increase business/sales activities by understanding your competitors’ businesses better.
• Recognize potential partnerships and suppliers.
Key Highlights
Hutchison China MediTech Limited (Chi-Med), is a biopharmaceutical company that endeavors to discover, develop and commercialize pharmaceuticals and health-related consumer products. The company's Innovation Platform, Hutchison MediPharma Limited focuses on the discovery and development of novel therapeutics in cancer and autoimmune diseases for the worldwide market and Commercial Platform focuses on the manufacture, marketing and distribution of prescription drugs and consumer health products in China. Chi-Med offers its products in China through sales team including medical representatives. It distributes its prescription drugs to hospitals across China. The company is majority owned by CK Hutchison Holdings Limited, the multinational conglomerate. Chi-Med is headquartered at Harcourt Road, Hong Kong.
ICD Research is a full-service strategic insight provider. We own, manage and build premium panels to help you learn about difficult-to-reach segments and get better ROI from your research budget. We interact with your specific target audiences, using state-of-the-art technology to unlock deeper, quicker and more cost effective insight. ICD is the research and business information arm of Progressive Digital Media Group. ICD provides industry-leading market research and business information. Our products and services help companies make better decisions, win business and position themselves more effectively.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.